Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P20702

UPID:
ITAX_HUMAN

ALTERNATIVE NAMES:
CD11 antigen-like family member C; Leu M5; Leukocyte adhesion glycoprotein p150,95 alpha chain; Leukocyte adhesion receptor p150,95

ALTERNATIVE UPACC:
P20702; Q8IVA6

BACKGROUND:
The Integrin alpha-X protein, known for its alternative names such as Leukocyte adhesion glycoprotein p150,95 alpha chain, is a key player in the immune response. It serves as a receptor for fibrinogen, facilitating cell-cell interaction during inflammation. Its recognition of the G-P-R sequence in fibrinogen and its role in monocyte adhesion and chemotaxis underscore its critical function in the immune system.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Integrin alpha-X unveils potential pathways for therapeutic intervention. Given its central role in mediating inflammatory responses and cell adhesion, targeting this protein could lead to innovative treatments for managing immune and inflammatory conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.